Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trialHilko Ardon, Steven De Vleeschouwer, Frank Van Calenbergh et al.|Cancer Immunology Immunotherapy|2012Cited by 162
Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trialMartin J. van den Bent, Ahmed Idbaïh, Martin Klein et al.|The Lancet Oncology|2018Cited by 131
Final results of the EORTC Brain Tumor Group randomized phase II TAVAREC trial on temozolomide with or without bevacizumab in 1st recurrence grade II/III glioma without 1p/19q co-deletion.Martin J. van den Bent, Martin Klein, Marion Smits et al.|Journal of Clinical Oncology|2017Cited by 10
NCOG-08. NEUROCOGNITIVE FUNCTIONING IN EORTC BRAIN TUMOR GROUP RANDOMIZED PHASE II TAVAREC TRIAL (EORTC 26091, NCT01164189) ON TEMOZOLOMIDE WITH OR WITHOUT BEVACIZUMAB in 1p/19q INTACT RECURRENT GRADE II AND III GLIOMASMartin Klein, Martin J. van den Bent, Jaap C. Reijneveld et al.|Neuro-Oncology|2017Cited by 0
Supplementary Figure from Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC TrialKaspar Draaisma, Pim J. French, C. Mircea S. Tesileanu et al.|Unknown|2023Cited by 0